{"DataElement":{"publicId":"7850271","version":"2","preferredName":"COVID-19 Infection Medication Administered Type","preferredDefinition":"The type of medication used to treat the COVID-19 infection.","longName":"COV_INF_MED_ADM_TYP","context":"NIH","contextVersion":"1","DataElementConcept":{"publicId":"7850268","version":"1","preferredName":"COVID-19 Infection Medication Administered","preferredDefinition":"An acute infection of the respiratory tract that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Based on currently available information, SARS-CoV-2 is thought to mainly spread from person to person through respiratory droplets. Typically, there is a two- to 14-day incubation period and infected persons can present with no symptoms or mild to severe fever, dry cough, fatigue, and difficulty breathing. Dysgeusia, anosmia, and gastrointestinal and flu-like symptoms have also been reported. Older adults and persons of any age who have serious underlying medical conditions may be of higher risk for severe illness, including secondary infections, respiratory failure, and multi-organ dysfunction._A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product._The act of having given something (e.g., a medication or test).","longName":"7850310v1.0:2233610v1.0","context":"NIH","contextVersion":"1","ObjectClass":{"publicId":"7850310","version":"1","preferredName":"COVID-19 Infection Medication","preferredDefinition":"An acute infection of the respiratory tract that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Based on currently available information, SARS-CoV-2 is thought to mainly spread from person to person through respiratory droplets. Typically, there is a two- to 14-day incubation period and infected persons can present with no symptoms or mild to severe fever, dry cough, fatigue, and difficulty breathing. Dysgeusia, anosmia, and gastrointestinal and flu-like symptoms have also been reported. Older adults and persons of any age who have serious underlying medical conditions may be of higher risk for severe illness, including secondary infections, respiratory failure, and multi-organ dysfunction.:A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","longName":"C171133:C459","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"COVID-19 Infection","conceptCode":"C171133","definition":"An acute infection of the respiratory tract that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Based on currently available information, SARS-CoV-2 is thought to mainly spread from person to person through respiratory droplets. Typically, there is a two- to 14-day incubation period and infected persons can present with no symptoms or mild to severe fever, dry cough, fatigue, and difficulty breathing. Dysgeusia, anosmia, and gastrointestinal and flu-like symptoms have also been reported. Older adults and persons of any age who have serious underlying medical conditions may be of higher risk for severe illness, including secondary infections, respiratory failure, and multi-organ dysfunction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Medication","conceptCode":"C459","definition":"A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B9A870-4F8E-35D3-E053-4EBD850A1754","latestVersionIndicator":"Yes","beginDate":"2021-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-12-09","modifiedBy":"ONEDATA","dateModified":"2021-12-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B85353-2B2B-54FE-E053-4EBD850A7853","latestVersionIndicator":"Yes","beginDate":"2021-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-12-09","modifiedBy":"KUMMEROA","dateModified":"2022-02-14","changeDescription":"2022-2-14 ak Released per DW review. 2021-12-9 ak Created for Project 5 Tier 1.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7850270","version":"2","preferredName":"COVID-19 Infection Medication Type","preferredDefinition":"A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product._Something distinguishable as an identifiable class based on common qualities._An acute infection of the respiratory tract that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Based on currently available information, SARS-CoV-2 is thought to mainly spread from person to person through respiratory droplets. Typically, there is a two- to 14-day incubation period and infected persons can present with no symptoms or mild to severe fever, dry cough, fatigue, and difficulty breathing. Dysgeusia, anosmia, and gastrointestinal and flu-like symptoms have also been reported. Older adults and persons of any age who have serious underlying medical conditions may be of higher risk for severe illness, including secondary infections, respiratory failure, and multi-organ dysfunction._A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","longName":"COV_MED_TY","context":"NIH","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"85","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Statin","valueDescription":"HMG-CoA Reductase Inhibitor","ValueMeaning":{"publicId":"8067504","version":"1","preferredName":"HMG-CoA Reductase Inhibitor","longName":"8067504","preferredDefinition":"Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HMG-CoA Reductase Inhibitor","conceptCode":"C1655","definition":"Any substance that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis. Inhibition of HMG-CoA reductase acts to lower plasma cholesterol and lipoprotein levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D940E3AA-36E3-5918-E053-4EBD850AE344","latestVersionIndicator":"Yes","beginDate":"2022-03-02","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D940E3AA-36FE-5918-E053-4EBD850AE344","beginDate":"2022-03-02","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","deletedIndicator":"No"},{"value":"Norepinephrine Reuptake Inhibitor","valueDescription":"Norepinephrine Reuptake Inhibitor","ValueMeaning":{"publicId":"8064575","version":"1","preferredName":"Norepinephrine Reuptake Inhibitor","longName":"8064575","preferredDefinition":"Any agent that prevents the reuptake of (nor)epinephrine from the synapse into presynaptic neurons by the norepinephrine (NE) transporter (NET), thereby increasing the concentrations of (nor)epinephrine in the synaptic cleft and increasing adrenergic neurotransmission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Norepinephrine Reuptake Inhibitor","conceptCode":"C185721","definition":"Any agent that prevents the reuptake of (nor)epinephrine from the synapse into presynaptic neurons by the norepinephrine (NE) transporter (NET), thereby increasing the concentrations of (nor)epinephrine in the synaptic cleft and increasing adrenergic neurotransmission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D92AAFA0-6DA4-2772-E053-4EBD850A573B","latestVersionIndicator":"Yes","beginDate":"2022-03-01","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-01","modifiedBy":"ONEDATA","dateModified":"2022-03-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D92AAFA0-6DBF-2772-E053-4EBD850A573B","beginDate":"2022-03-01","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-01","modifiedBy":"ONEDATA","dateModified":"2022-03-01","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"5682953","version":"1","preferredName":"Unknown","longName":"5682953","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B4645-0FC6-0802-E053-F662850AB305","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3E23-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Other, Specify","valueDescription":"If Other, Specify","ValueMeaning":{"publicId":"7557010","version":"1","preferredName":"If Other, Specify","longName":"7557010","preferredDefinition":"A directive to specify when the listed responses are not sufficient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"If Other, Specify","conceptCode":"C157101","definition":"A directive to specify when the listed responses are not sufficient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9D26A12-EF66-4B33-E053-4EBD850ACC4C","latestVersionIndicator":"Yes","beginDate":"2021-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-01-26","modifiedBy":"CLOHNES","dateModified":"2022-06-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3E2D-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Hydrocortisone","valueDescription":"Therapeutic Hydrocortisone","ValueMeaning":{"publicId":"2578183","version":"1","preferredName":"Therapeutic Hydrocortisone","longName":"2578183","preferredDefinition":"A synthetic or semisynthetic analog of natural hydrocortisone hormone produced by the adrenal glands with primary glucocorticoid and minor mineralocorticoid effects. As a glucocorticoid receptor agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppresses immune and inflammatory responses. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Hydrocortisone","conceptCode":"C555","definition":"A synthetic or semisynthetic analog of natural hydrocortisone hormone produced by the adrenal glands with primary glucocorticoid and minor mineralocorticoid effects. As a glucocorticoid receptor agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppresses immune and inflammatory responses. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE74-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3E37-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Prednisone/prednisolone","valueDescription":"Prednisone Or Prednisolone","ValueMeaning":{"publicId":"7850304","version":"1","preferredName":"Prednisone Or Prednisolone","longName":"7850304","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prednisolone","conceptCode":"C769","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B99329-E67F-58B4-E053-4EBD850A7DC2","latestVersionIndicator":"Yes","beginDate":"2021-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-12-09","modifiedBy":"KUMMEROA","dateModified":"2023-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3E41-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Methylprednisolone","valueDescription":"Methylprednisolone","ValueMeaning":{"publicId":"2578269","version":"1","preferredName":"Methylprednisolone","longName":"2578269","preferredDefinition":"A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methylprednisolone","conceptCode":"C647","definition":"A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FECA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3E4B-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Fludrocortisone","valueDescription":"Fludrocortisone","ValueMeaning":{"publicId":"3305275","version":"1","preferredName":"Fludrocortisone","longName":"3305275","preferredDefinition":"A synthetic corticosteroid with antiinflammatory and antiallergic properties. Fludrocortisone is a mineralocorticoid receptor and glucocorticoid receptor agonist that binds to cytoplasmic receptors, translocates to the nucleus and subsequently initiates the transcription of glucocorticoid-responsive genes such as lipocortins to inhibit phospholipase A2. This prevents the release of arachidonic acid, a precursor to prostaglandins and leukotrienes, both important mediators in the pro-inflammatory response mechanism. In addition, this agent exerts its mineralocorticoid effect on the distal tubules and collecting ducts of the kidney by inducing permease, an enzyme that regulates Na+ permeability in cells, thereby enhancing Na+ reabsorption and water retention as well as increasing K+, H+ excretion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fludrocortisone","conceptCode":"C71629","definition":"A synthetic corticosteroid with antiinflammatory and antiallergic properties. Fludrocortisone is a mineralocorticoid receptor and glucocorticoid receptor agonist that binds to cytoplasmic receptors, translocates to the nucleus and subsequently initiates the transcription of glucocorticoid-responsive genes such as lipocortins to inhibit phospholipase A2. This prevents the release of arachidonic acid, a precursor to prostaglandins and leukotrienes, both important mediators in the pro-inflammatory response mechanism. In addition, this agent exerts its mineralocorticoid effect on the distal tubules and collecting ducts of the kidney by inducing permease, an enzyme that regulates Na+ permeability in cells, thereby enhancing Na+ reabsorption and water retention as well as increasing K+, H+ excretion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1A4B8-0D2E-8518-E040-BB89AD435A01","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3E55-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Ipratropium","valueDescription":"Ipratropium","ValueMeaning":{"publicId":"3076449","version":"1","preferredName":"Ipratropium","longName":"3076449","preferredDefinition":"A synthetic derivative of the alkaloid atropine with anticholinergic properties. Ipratropium antagonizes the actions of acetylcholine at parasympathetic postganglionic effector cell junctions. When inhaled, ipratropium binds competitively to cholinergic receptors in the bronchial smooth muscle thereby blocking the bronchoconstrictor actions of the acetylcholine (Ach) mediated vagal impulses. Inhibition of the vagal tone leads to dilation of the large central airways resulting in bronchodilation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipratropium","conceptCode":"C61794","definition":"A synthetic derivative of the alkaloid atropine with anticholinergic properties. Ipratropium antagonizes the actions of acetylcholine at parasympathetic postganglionic effector cell junctions. When inhaled, ipratropium binds competitively to cholinergic receptors in the bronchial smooth muscle thereby blocking the bronchoconstrictor actions of the acetylcholine (Ach) mediated vagal impulses. Inhibition of the vagal tone leads to dilation of the large central airways resulting in bronchodilation.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"852693AD-C690-32F2-E040-BB89AD436CB9","latestVersionIndicator":"Yes","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3E5F-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Albuterol","valueDescription":"Albuterol (Proventil, Ventolin, Volmax)","ValueMeaning":{"publicId":"2575988","version":"1","preferredName":"Albuterol (Proventil, Ventolin, Volmax)","longName":"2575988","preferredDefinition":"A racemic mixture with a 1:1 ratio of the r-isomer, levalbuterol, and s-albuterol. It is a short-acting beta2-adrenergic agonist with its main clinical use in asthma. (MeSH)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Albuterol","conceptCode":"C215","definition":"A racemic mixture of the r-isomer levalbuterol and s-albuterol, a short-acting sympathomimetic agent with bronchodilator activity. Albuterol stimulates beta-2 adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP concentrations relax bronchial smooth muscle, relieve bronchospasms, and reduce inflammatory cell mediator release, especially from mast cells. Albuterol although to a lesser extent, also stimulates beta-1 adrenergic receptors, thereby increasing the force and rate of myocardial contraction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5E1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2010-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3E69-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Ribavirin","valueDescription":"Ribavirin","ValueMeaning":{"publicId":"5633390","version":"1","preferredName":"Ribavirin","longName":"5633390","preferredDefinition":"A synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ribavirin","conceptCode":"C807","definition":"A synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46EDA67D-D730-41DC-E053-F662850A0513","latestVersionIndicator":"Yes","beginDate":"2017-01-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3E73-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Favipiravir","valueDescription":"Favipiravir","ValueMeaning":{"publicId":"7850275","version":"1","preferredName":"Favipiravir","longName":"7850275","preferredDefinition":"A pyrazinecarboxamide derivative with activity against RNA viruses. Favipiravir is converted to the ribofuranosyltriphosphate derivative by host enzymes and selectively inhibits the influenza viral RNA-dependent RNA polymerase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Favipiravir","conceptCode":"C81605","definition":"A pyrazinecarboxamide derivative with activity against RNA viruses. Favipiravir is converted to the ribofuranosyltriphosphate derivative by host enzymes and selectively inhibits the influenza viral RNA-dependent RNA polymerase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B8E3D6-7E67-4D8B-E053-4EBD850A5E4B","latestVersionIndicator":"Yes","beginDate":"2021-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-12-09","modifiedBy":"ONEDATA","dateModified":"2021-12-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3E7D-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Lopinavir/Ritonavir","valueDescription":"Lopinavir/Ritonavir","ValueMeaning":{"publicId":"2578201","version":"1","preferredName":"Lopinavir/Ritonavir","longName":"2578201","preferredDefinition":"A combination anti-HIV protease inhibitor from Abbott Laboratories.  Brand name is Kaletra.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lopinavir/Ritonavir","conceptCode":"C2096","definition":"A fixed combination of two protease inhibitors, lopinavir and ritonavir, used to treat human immunodeficiency virus (HIV) infection. The ritonavir in the combination drug increases the concentration and biological half-life of lopinavir but is not present in sufficient concentration to act as a protease inhibitor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE86-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3E87-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Remdesivir","valueDescription":"Remdesivir","ValueMeaning":{"publicId":"7850277","version":"1","preferredName":"Remdesivir","longName":"7850277","preferredDefinition":"A prodrug of an adenosine triphosphate (ATP) analog, with potential antiviral activity against a variety of RNA viruses. Upon administration, remdesivir, being a prodrug, is metabolized into its active form GS-441524. As an ATP analog, GS-441524 competes with ATP for incorporation into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription and decreases viral RNA production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Remdesivir","conceptCode":"C152185","definition":"A prodrug of an adenosine triphosphate (ATP) analog, with potential antiviral activity against a variety of RNA viruses. Upon administration, remdesivir, being a prodrug, is metabolized into its active form GS-441524. As an ATP analog, GS-441524 competes with ATP for incorporation into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription and decreases viral RNA production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B8E3D6-7E97-4D8B-E053-4EBD850A5E4B","latestVersionIndicator":"Yes","beginDate":"2021-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-12-09","modifiedBy":"GDEEN","dateModified":"2022-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3E91-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Inhaled steroids","valueDescription":"Inhalation Steroid Therapy","ValueMeaning":{"publicId":"7850292","version":"1","preferredName":"Inhalation Steroid Therapy","longName":"7850292","preferredDefinition":"To draw in with the breath through the nose or mouth.: Treatment with corticosteroid drugs to reduce swelling, pain, and other symptoms of inflammation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inhalation","conceptCode":"C95464","definition":"To draw in with the breath through the nose or mouth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Steroid Therapy","conceptCode":"C15370","definition":"The use of exogenous steroids for the treatment of any disease or disorder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B95CA4-675C-07E3-E053-4EBD850A7999","latestVersionIndicator":"Yes","beginDate":"2021-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-12-09","modifiedBy":"ONEDATA","dateModified":"2021-12-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3E9B-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Insulin","valueDescription":"Insulin","ValueMeaning":{"publicId":"2561935","version":"1","preferredName":"Insulin","longName":"2561935","preferredDefinition":"(IN-su-lin) A hormone made by the islet cells of the pancreas. Insulin controls the amount of sugar in the blood by moving it into the cells, where it can be used by the body for energy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Insulin","conceptCode":"C2271","definition":"Insulin (51 aa, ~6 kDa) is encoded by the human INS gene. This protein is involved in the direct regulation of glucose metabolism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BEFC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-22","endDate":null,"createdBy":"JASUR","dateCreated":"2002-07-22","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3EA5-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"NSAID-Ibuprofen","valueDescription":"Nonsteroidal Antiinflammatory Drug","ValueMeaning":{"publicId":"2578060","version":"1","preferredName":"Nonsteroidal Antiinflammatory Drug","longName":"2578060","preferredDefinition":"Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain NSAIDs also may inhibit lipoxygenase enzymes or phospholipase C or may modulate T-cell function. (AMA Drug Evaluations Annual, 1994, p 1814-5)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nonsteroidal Antiinflammatory Drug","conceptCode":"C257","definition":"A pharmacological agent that is not a steroid and has potential anti-inflammatory, analgesic, antipyretic and anti-platelet activities. Most nonsteroidal anti-inflammatory drugs (NSAIDs) act by inhibiting the conversion of arachidonic acid to the precursors of prostaglandin and thromboxane by cyclooxygenase enzymes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FDF9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-01","modifiedBy":"ONEDATA","dateModified":"2006-03-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3EAF-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Tumor necrosis factor (TNF) inhibitors (i.e. infliximab, etanercept, adalimumab)","valueDescription":"Tumor Necrosis Factor Inhibitor","ValueMeaning":{"publicId":"7850293","version":"1","preferredName":"Tumor Necrosis Factor Inhibitor","longName":"7850293","preferredDefinition":"Tumor necrosis factor (233 aa, ~26 kDa) is encoded by the human TNF gene. This protein is involved in the induction of cytokine expression, the stimulation of cell proliferation and the positive regulation of cell differentiation.: A class of substances that binds to and inhibits the function or activity of a target.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Necrosis Factor","conceptCode":"C20535","definition":"Tumor necrosis factor (233 aa, ~26 kDa) is encoded by the human TNF gene. This protein is involved in the induction of cytokine expression, the stimulation of cell proliferation and the positive regulation of cell differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Inhibitor","conceptCode":"C154898","definition":"A class of substances that binds to and inhibits the function or activity of a target.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B95CA4-67A0-07E3-E053-4EBD850A7999","latestVersionIndicator":"Yes","beginDate":"2021-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-12-09","modifiedBy":"ONEDATA","dateModified":"2021-12-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3EB9-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Interferon","valueDescription":"Interferon","ValueMeaning":{"publicId":"3119698","version":"1","preferredName":"Interferon","longName":"3119698","preferredDefinition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon","conceptCode":"C20493","definition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AE1E2A1-466C-6C31-E040-BB89AD434C6B","latestVersionIndicator":"Yes","beginDate":"2010-07-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-08","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3EC3-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"SARS-CoV-2 Monoclonal antibodies","valueDescription":"SARS Coronavirus 2 Monoclonal Antibody","ValueMeaning":{"publicId":"7850294","version":"1","preferredName":"SARS Coronavirus 2 Monoclonal Antibody","longName":"7850294","preferredDefinition":"A positive-sense single-stranded RNA virus in the genus Betacoronavirus. It is the causative agent of the 2019-2020 severe acute respiratory syndrome outbreak.: An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"SARS Coronavirus 2","conceptCode":"C169076","definition":"A positive-sense single-stranded RNA virus in the genus Betacoronavirus. It is the causative agent of the 2019-2020 severe acute respiratory syndrome outbreak.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B95CA4-67D0-07E3-E053-4EBD850A7999","latestVersionIndicator":"Yes","beginDate":"2021-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-12-09","modifiedBy":"MAESKEB","dateModified":"2022-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3ECD-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Direct oral anticoagulant (DOAC)","valueDescription":"Direct Oral Anticoagulant","ValueMeaning":{"publicId":"7850295","version":"1","preferredName":"Direct Oral Anticoagulant","longName":"7850295","preferredDefinition":"An agent taken orally to prevent blood clot formation by directly inhibiting certain coagulation factors including thrombin (factor IIa) or factor Xa.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Direct Oral Anticoagulant","conceptCode":"C180619","definition":"An agent taken orally to prevent blood clot formation by directly inhibiting certain coagulation factors including thrombin (factor IIa) or factor Xa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B95CA4-67F5-07E3-E053-4EBD850A7999","latestVersionIndicator":"Yes","beginDate":"2021-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-12-09","modifiedBy":"ONEDATA","dateModified":"2021-12-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3ED7-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Warfarin","valueDescription":"Warfarin","ValueMeaning":{"publicId":"3191443","version":"1","preferredName":"Warfarin","longName":"3191443","preferredDefinition":"A synthetic anticoagulant. Warfarin appears to inhibit the regeneration of vitamin K1 epoxide and so the synthesis of vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. This inhibition results in a sequential depression of Factors VII, IX, X and II activities. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of gamma-carboxyglutamic acid residues in these proteins which are essential for biological activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Warfarin","conceptCode":"C945","definition":"A synthetic anticoagulant. Warfarin inhibits the regeneration of vitamin K1 epoxide and so the synthesis of vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. This inhibition results in a sequential depression of Factors VII, IX, X and II activities. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of gamma-carboxyglutamic acid residues in these proteins which are essential for biological activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BF5A32C-4FD0-EC58-E040-BB89AD437BD3","latestVersionIndicator":"Yes","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3EE1-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Enoxaparin","valueDescription":"Enoxaparin","ValueMeaning":{"publicId":"2576814","version":"1","preferredName":"Enoxaparin","longName":"2576814","preferredDefinition":"A drug used to prevent blood clots.  It belongs to the family of drugs called anticoagulants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enoxaparin","conceptCode":"C1452","definition":"A low molecular weight, synthetic heparin. As an anticoagulant/antithrombotic agent, enoxaprin's mechanism of action is similar to that of heparin, although it exhibits a higher ratio of anti-Factor Xa to anti-Factor IIa activity. This agent also has anti-inflammatory properties, inhibiting monocyte adhesion to tumor necrosis factor alpha- or lipopolysaccharide-activated endothelial cells.  Compared to unfractionated heparins, the use of enoxaparin is associated with lower incidences of osteoporosis and heparin-induced thrombocytopenia. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F91B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3EEB-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Antiplatelets/Aspirin therapy","valueDescription":"Antiplatelet Agent","ValueMeaning":{"publicId":"3191466","version":"1","preferredName":"Antiplatelet Agent","longName":"3191466","preferredDefinition":"An agent that inhibits platelet aggregation and reduces coagulation in the circulatory system. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antiplatelet Agent","conceptCode":"C1327","definition":"An agent that inhibits platelet aggregation and reduces coagulation in the circulatory system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C03939E-97BF-2D26-E040-BB89AD4356ED","latestVersionIndicator":"Yes","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3EF5-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Dexamethasone","valueDescription":"Dexamethasone","ValueMeaning":{"publicId":"3028376","version":"1","preferredName":"Dexamethasone","longName":"3028376","preferredDefinition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04) [Source: NCI]","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8223B6A1-980B-C0E8-E040-BB89AD43538F","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-03-19","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3EFF-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Heparin","valueDescription":"Heparin","ValueMeaning":{"publicId":"2567254","version":"1","preferredName":"Heparin","longName":"2567254","preferredDefinition":"A sulfur-rich glycosaminoglycan with anticoagulant property. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors, such as factors IX, X, XI, and XII, thereby preventing the polymerization of fibrinogen to fibrin and the subsequent formation of clots.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Heparin","conceptCode":"C539","definition":"A sulfur-rich glycosaminoglycan with anticoagulant property. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors, such as factors IX, X, XI, and XII, thereby preventing the polymerization of fibrinogen to fibrin and the subsequent formation of clots.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D3C3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3F09-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Anakinra","valueDescription":"Anakinra","ValueMeaning":{"publicId":"7092700","version":"1","preferredName":"Anakinra","longName":"7092700","preferredDefinition":"A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anakinra","conceptCode":"C38717","definition":"A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D63FC7-EB90-7B51-E053-F662850A2C3A","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3F13-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Intravenous Immunoglobulin Therapy","valueDescription":"Intravenous Immunoglobulin Therapy","ValueMeaning":{"publicId":"6051439","version":"1","preferredName":"Intravenous Immunoglobulin Therapy","longName":"6051439","preferredDefinition":"The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Immunoglobulin Therapy","conceptCode":"C121331","definition":"The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62E6E09D-AF1C-7E3A-E053-F662850A049D","latestVersionIndicator":"Yes","beginDate":"2018-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-01-16","modifiedBy":"KUMMEROA","dateModified":"2023-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3F1D-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Mesenchymal Stem Cell","valueDescription":"Mesenchymal Stem Cell","ValueMeaning":{"publicId":"4197222","version":"1","preferredName":"Mesenchymal Stem Cell","longName":"4197222","preferredDefinition":"An undifferentiated stromal cell with the ability to develop into the cells that form distinct mesenchymal tissues; such as bone, muscle, connective tissue, blood vessels, and lymphatic tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mesenchymal Stem Cell","conceptCode":"C43423","definition":"An undifferentiated stromal cell with the ability to develop into the cells that form distinct mesenchymal tissues; such as bone, muscle, connective tissue, blood vessels, and lymphatic tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F1A516-3B13-2DD9-E040-BB89AD434115","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"COLBERTM","dateCreated":"2014-03-06","modifiedBy":"MAESKEB","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3F27-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"COVID-19 Convalescent Plasma","valueDescription":"COVID-19 Convalescent Plasma","ValueMeaning":{"publicId":"7850297","version":"1","preferredName":"COVID-19 Convalescent Plasma","longName":"7850297","preferredDefinition":"Plasma that has been collected from patients who have recovered from the novel coronavirus disease, COVID-19. This plasma contains antibodies developed against the SARS-CoV-2 virus and is being investigated for the treatment of COVID-19.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"COVID-19 Convalescent Plasma","conceptCode":"C171633","definition":"Plasma that has been collected from patients who have recovered from the novel coronavirus disease, COVID-19. This plasma contains antibodies developed against the SARS-CoV-2 virus and is being investigated for the treatment of COVID-19.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B95CA4-6896-07E3-E053-4EBD850A7999","latestVersionIndicator":"Yes","beginDate":"2021-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-12-09","modifiedBy":"MAESKEB","dateModified":"2022-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3F31-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Losartan","valueDescription":"Losartan","ValueMeaning":{"publicId":"7850299","version":"1","preferredName":"Losartan","longName":"7850299","preferredDefinition":"A non-peptide angiotensin II antagonist with antihypertensive activity. Upon administration, losartan and its active metabolite selectively and competitively blocks the binding of angiotensin II to the angiotensin I (AT1) receptor. This blocks the vasoconstricting and aldosterone-secreting actions of angiotensin II, leading to a decrease in blood pressure. Angiotensin II, formed from angiotensin I by angiotensin-converting enzyme (ACE), stimulates the adrenal cortex to synthesize and secrete aldosterone, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Losartan","conceptCode":"C66869","definition":"A non-peptide angiotensin II antagonist with antihypertensive activity. Upon administration, losartan and its active metabolite selectively and competitively blocks the binding of angiotensin II to the angiotensin I (AT1) receptor. This blocks the vasoconstricting and aldosterone-secreting actions of angiotensin II, leading to a decrease in blood pressure. Angiotensin II, formed from angiotensin I by angiotensin-converting enzyme (ACE), stimulates the adrenal cortex to synthesize and secrete aldosterone, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B95CA4-68BC-07E3-E053-4EBD850A7999","latestVersionIndicator":"Yes","beginDate":"2021-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-12-09","modifiedBy":"ONEDATA","dateModified":"2021-12-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3F3B-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Azithromycin","valueDescription":"Azithromycin","ValueMeaning":{"publicId":"2575656","version":"1","preferredName":"Azithromycin","longName":"2575656","preferredDefinition":"An azalide, derived from erythromycin, and a member of a subclass of macrolide antibiotics with bacteriocidal and bacteriostatic activities. Azithromycin reversibly binds to the 50S ribosomal subunit of the 70S ribosome of sensitive microorganisms, thereby inhibiting the translocation step of protein synthesis, wherein a newly synthesized peptidyl tRNA molecule moves from the acceptor site on the ribosome to the peptidyl (donor) site, and consequently inhibiting RNA-dependent protein synthesis leading to cell growth inhibition and cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azithromycin","conceptCode":"C28844","definition":"An azalide, derived from erythromycin, and a member of a subclass of macrolide antibiotics with bacteriocidal and bacteriostatic activities. Azithromycin reversibly binds to the 50S ribosomal subunit of the 70S ribosome of sensitive microorganisms, thereby inhibiting the translocation step of protein synthesis, wherein a newly synthesized peptidyl tRNA molecule moves from the acceptor site on the ribosome to the peptidyl (donor) site, and consequently inhibiting RNA-dependent protein synthesis leading to cell growth inhibition and cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F495-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"TAYLORT","dateModified":"2018-05-15","changeDescription":"5/15/18 tt added concept definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3F45-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Siltuximab","valueDescription":"Siltuximab","ValueMeaning":{"publicId":"5621734","version":"1","preferredName":"Siltuximab","longName":"5621734","preferredDefinition":"A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Siltuximab","conceptCode":"C61084","definition":"A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BCF0-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3F4F-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Tocilizumab","valueDescription":"Tocilizumab","ValueMeaning":{"publicId":"4618052","version":"1","preferredName":"Tocilizumab","longName":"4618052","preferredDefinition":"A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. Il-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders and certain types of cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tocilizumab","conceptCode":"C84217","definition":"A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0953B289-65BB-6299-E050-BB89AD4328C8","latestVersionIndicator":"Yes","beginDate":"2014-12-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-12-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3F59-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Chloroquine","valueDescription":"Chloroquine","ValueMeaning":{"publicId":"7850300","version":"1","preferredName":"Chloroquine","longName":"7850300","preferredDefinition":"A 4-aminoquinoline with antimalarial, anti-inflammatory, and potential chemosensitization and radiosensitization activities. Although the mechanism is not well understood, chloroquine is shown to inhibit the parasitic enzyme heme polymerase that converts the toxic heme into non-toxic hemazoin, thereby resulting in the accumulation of toxic heme within the parasite. This agent may also interfere with the biosynthesis of nucleic acids. Chloroquine's potential chemosensitizing and radiosensitizing activities in cancer may be related to its inhibition of autophagy, a cellular mechanism involving lysosomal degradation that minimizes the production of reactive oxygen species (ROS) related to tumor reoxygenation and tumor exposure to chemotherapeutic agents and radiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chloroquine","conceptCode":"C61671","definition":"A 4-aminoquinoline with antimalarial, anti-inflammatory, and potential chemosensitization and radiosensitization activities. Although the mechanism is not well understood, chloroquine is shown to inhibit the parasitic enzyme heme polymerase that converts the toxic heme into non-toxic hemazoin, thereby resulting in the accumulation of toxic heme within the parasite. This agent may also interfere with the biosynthesis of nucleic acids. Chloroquine's potential chemosensitizing and radiosensitizing activities in cancer may be related to its inhibition of autophagy, a cellular mechanism involving lysosomal degradation that minimizes the production of reactive oxygen species (ROS) related to tumor reoxygenation and tumor exposure to chemotherapeutic agents and radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B95CA4-68FF-07E3-E053-4EBD850A7999","latestVersionIndicator":"Yes","beginDate":"2021-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-12-09","modifiedBy":"ONEDATA","dateModified":"2021-12-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3F63-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Hydroxychloroquine","valueDescription":"Hydroxychloroquine","ValueMeaning":{"publicId":"3379074","version":"1","preferredName":"Hydroxychloroquine","longName":"3379074","preferredDefinition":"A substance that decreases immune responses in the body.  It is used to treat some autoimmune diseases, and is being studied as a treatment for graft-versus-host disease. Hydroxychloroquine belongs to the family of drugs called antiprotozoals.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydroxychloroquine","conceptCode":"C557","definition":"A 4-aminoquinoline with immunosuppressive, antiautophagy, and antimalarial activities. Although the precise mechanism of action is unknown, hydroxychloroquine may suppress immune function by interfering with the processing and presentation of antigens and the production of cytokines. As a lysosomotropic agent, hydroxychloroquine raises intralysosomal pH, impairing autophagic protein degradation; hydroxychloroquine-mediated accumulation of ineffective autophagosomes may result in cell death in tumor cells reliant on autophagy for survival.  In addition, this agent is highly active against the erythrocytic forms of P. vivax and malariae and most strains of P. falciparum but not the gametocytes of P. falciparum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-AF6A-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3F6D-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Ivermectin","valueDescription":"Ivermectin","ValueMeaning":{"publicId":"2578208","version":"1","preferredName":"Ivermectin","longName":"2578208","preferredDefinition":"A macrocyclic lactone derived from Streptomyces avermitilis with antiparasitic activity. Ivermectin exerts its anthelmintic effect via activating glutamate-gated chloride channels expressed on nematode neurons and pharyngeal muscle cells. Distinct from the channel opening induced by endogenous glutamate transmitter, ivermectin-activated channels open very slowly but essentially irreversibly. As a result, neurons or muscle cells remain at either hyperpolarisation or depolarization state, thereby resulting in paralysis and death of the parasites. Ivermectin does not readily pass the mammal blood-brain barrier to the central nervous system where glutamate-gated chloride channels locate, hence the hosts are relatively resistant to the effects of this agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ivermectin","conceptCode":"C61796","definition":"An orally bioavailable macrocyclic lactone derived from Streptomyces avermitilis, with antiparasitic and potential anti-viral activities. Upon administration, ivermectin exerts its anthelmintic effect through binding and activating glutamate-gated chloride channels (GluCls) expressed on nematode neurons and pharyngeal muscle cells. This causes increased permeability of chloride ions, causing a state of hyperpolarization and results in the paralysis and death of the parasite. Ivermectin may exerts its antiviral effect, including its potential activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), by binding to the importin (IMP) alpha/beta1 heterodimer, which is responsible for the nuclear import of viral proteins such as the integrase (IN) protein. This inhibits nuclear import of host and viral proteins and may inhibit viral replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE8D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"REEVESD","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3F77-4AB3-E053-4EBD850A5869","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Investigational drug","valueDescription":"Investigational New Drug","ValueMeaning":{"publicId":"2959607","version":"1","preferredName":"Investigational New Drug","longName":"2959607","preferredDefinition":"A new drug or biological drug that is used in a clinical investigation. The term also includes a biological product that is used in vitro for diagnostic purposes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Investigational New Drug","conceptCode":"C49135","definition":"A new drug or biological drug that is used in a clinical investigation. The term also includes a biological product that is used in vitro for diagnostic purposes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77FB5264-5E08-80D2-E040-BB89AD4379BB","latestVersionIndicator":"Yes","beginDate":"2009-11-09","endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"MAESKEB","dateModified":"2022-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3F88-4AB3-E053-4EBD850A5869","beginDate":"2022-02-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Molnupiravir","valueDescription":"Molnupiravir","ValueMeaning":{"publicId":"8062014","version":"1","preferredName":"Molnupiravir","longName":"8062014","preferredDefinition":"An orally bioavailable prodrug of EIDD-1931, the synthetic ribonucleoside derivative N4-hydroxycytidine and ribonucleoside analog, with potential antiviral activity against a variety of RNA viruses. Upon oral administration, molnupiravir, being a prodrug, is metabolized into its active form EIDD-1931 and converted into its triphosphate (TP) form. The TP form of EIDD-1931 is incorporated into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription and decreases viral RNA production, and viral RNA replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Molnupiravir","conceptCode":"C172633","definition":"An orally bioavailable prodrug of EIDD-1931, the synthetic ribonucleoside derivative N4-hydroxycytidine and ribonucleoside analog, with potential antiviral activity against a variety of RNA viruses. Upon oral administration, molnupiravir, being a prodrug, is metabolized into its active form EIDD-1931 and converted into its triphosphate (TP) form. The TP form of EIDD-1931 is incorporated into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription and decreases viral RNA production, and viral RNA replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D918E1F9-3F95-4AB3-E053-4EBD850A5869","latestVersionIndicator":"Yes","beginDate":"2022-02-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"GDEEN","dateModified":"2022-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3FAE-4AB3-E053-4EBD850A5869","beginDate":"2022-02-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"JAK inhibitor","valueDescription":"JAK Inhibitor","ValueMeaning":{"publicId":"8062016","version":"1","preferredName":"JAK Inhibitor","longName":"8062016","preferredDefinition":"Any agent that targets, binds to and inhibits the activity of one or more of the Janus kinase family of enzymes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"JAK Inhibitor","conceptCode":"C172200","definition":"Any agent that targets, binds to and inhibits the activity of one or more of the Janus kinase family of enzymes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D918E1F9-3FBB-4AB3-E053-4EBD850A5869","latestVersionIndicator":"Yes","beginDate":"2022-02-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3FD6-4AB3-E053-4EBD850A5869","beginDate":"2022-02-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Corticosteroids","valueDescription":"Corticosteroid","ValueMeaning":{"publicId":"3951357","version":"1","preferredName":"Corticosteroid","longName":"3951357","preferredDefinition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corticosteroid","conceptCode":"C2322","definition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAE91AA1-BCFE-7D56-E040-BB89AD4361DC","latestVersionIndicator":"Yes","beginDate":"2013-11-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-3FE0-4AB3-E053-4EBD850A5869","beginDate":"2022-02-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Anti-inflammatory antibodies","valueDescription":"Anti-inflammatory Antibody","ValueMeaning":{"publicId":"8062017","version":"1","preferredName":"Anti-inflammatory Antibody","longName":"8062017","preferredDefinition":"Having to do with reducing inflammation.: A protein made by plasma cells (a type of white blood cell) in response to an antigen (a substance that causes the body to make a specific immune response). Each antibody can bind to only one specific antigen. The purpose of this binding is to help destroy the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-inflammatory","conceptCode":"C28347","definition":"Having to do with reducing inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antibody","conceptCode":"C16295","definition":"A type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D918E1F9-3FED-4AB3-E053-4EBD850A5869","latestVersionIndicator":"Yes","beginDate":"2022-02-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D918E1F9-4008-4AB3-E053-4EBD850A5869","beginDate":"2022-02-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7850309","version":"1","preferredName":"COVID-19 Infection Medication Type","preferredDefinition":"An acute infection of the respiratory tract that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Based on currently available information, SARS-CoV-2 is thought to mainly spread from person to person through respiratory droplets. Typically, there is a two- to 14-day incubation period and infected persons can present with no symptoms or mild to severe fever, dry cough, fatigue, and difficulty breathing. Dysgeusia, anosmia, and gastrointestinal and flu-like symptoms have also been reported. Older adults and persons of any age who have serious underlying medical conditions may be of higher risk for severe illness, including secondary infections, respiratory failure, and multi-organ dysfunction.:A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.:Something distinguishable as an identifiable class based on common qualities.","longName":"C171133:C459:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"COVID-19 Infection","conceptCode":"C171133","definition":"An acute infection of the respiratory tract that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Based on currently available information, SARS-CoV-2 is thought to mainly spread from person to person through respiratory droplets. Typically, there is a two- to 14-day incubation period and infected persons can present with no symptoms or mild to severe fever, dry cough, fatigue, and difficulty breathing. Dysgeusia, anosmia, and gastrointestinal and flu-like symptoms have also been reported. Older adults and persons of any age who have serious underlying medical conditions may be of higher risk for severe illness, including secondary infections, respiratory failure, and multi-organ dysfunction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Medication","conceptCode":"C459","definition":"A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B99329-E6CE-58B4-E053-4EBD850A7DC2","latestVersionIndicator":"Yes","beginDate":"2021-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-12-09","modifiedBy":"ONEDATA","dateModified":"2021-12-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D918E1F9-3E0D-4AB3-E053-4EBD850A5869","latestVersionIndicator":"Yes","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"MAESKEB","dateModified":"2022-03-02","changeDescription":"2022-2-14 ak Released per DW review. 2021-12-9 ak Created for Project 5 Tier 1. 2022-02-08 versioned per Denise W to add PVs bsm.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"7244861","version":"1","longName":"COVID-19","context":"NCIP","ClassificationSchemeItems":[{"publicId":"8038915","version":"1","longName":"NIH","context":"NCIP"},{"publicId":"8038916","version":"1","longName":"Project 5 CDEs","context":"NCIP"}]},{"publicId":"7977821","version":"1","longName":"Project 5 COVID","context":"NIH","ClassificationSchemeItems":[{"publicId":"7977823","version":"1","longName":"Tier 1","context":"NIH"}]}],"AlternateNames":[{"name":"COVID-19 Specific Medication Type","type":"NIH COVID","context":"NIH"},{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"What medications did the pati","type":"Preferred Question Text","description":"What medications did the patient take to treat COVID-19?","url":null,"context":"NIH"},{"name":"COG CRF text 1","type":"Alternate Question Text","description":"Which of the medications were received?","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D918CA45-9E85-5170-E053-4EBD850AE971","latestVersionIndicator":"Yes","beginDate":"2021-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"COOPERJ","dateModified":"2022-03-01","changeDescription":"2022-2-14 ak Released per DW review. 2021-12-14 ak Created for Project 5 Tier 1. 2022-02-28 versioned per Denise W. to add PVs bsm.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}